-
1
-
-
48349136889
-
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
-
Barrett J.C., et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 2008, 40:955-962.
-
(2008)
Nat. Genet.
, vol.40
, pp. 955-962
-
-
Barrett, J.C.1
-
2
-
-
84866065925
-
(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD
-
Chen C.Y., et al. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ. 2012, 19:1623-1633.
-
(2012)
Cell Death Differ.
, vol.19
, pp. 1623-1633
-
-
Chen, C.Y.1
-
3
-
-
84865032690
-
Brain penetrant LRRK2 inhibitor
-
Choi H.G., et al. Brain penetrant LRRK2 inhibitor. ACS Med. Chem. Lett. 2012, 3:658-662.
-
(2012)
ACS Med. Chem. Lett.
, vol.3
, pp. 658-662
-
-
Choi, H.G.1
-
4
-
-
84901669528
-
LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex
-
Cirnaru M.D., et al. LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Front. Mol. Neurosci. 2014, 7:49.
-
(2014)
Front. Mol. Neurosci.
, vol.7
, pp. 49
-
-
Cirnaru, M.D.1
-
5
-
-
78649389313
-
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
-
Cookson M.R. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat. Rev. Neurosci. 2010, 11:791-797.
-
(2010)
Nat. Rev. Neurosci.
, vol.11
, pp. 791-797
-
-
Cookson, M.R.1
-
6
-
-
77956655427
-
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization
-
Dzamko N., et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem. J. 2010, 430:405-413.
-
(2010)
Biochem. J.
, vol.430
, pp. 405-413
-
-
Dzamko, N.1
-
7
-
-
84862497413
-
The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling
-
Dzamko N., et al. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS One 2012, 7:e39132.
-
(2012)
PLoS One
, vol.7
-
-
Dzamko, N.1
-
8
-
-
84870051317
-
Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors
-
Estrada A.A., et al. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J. Med. Chem. 2012, 55:9416-9433.
-
(2012)
J. Med. Chem.
, vol.55
, pp. 9416-9433
-
-
Estrada, A.A.1
-
9
-
-
84894097684
-
Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors
-
Estrada A.A., et al. Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J. Med. Chem. 2014, 57:921-936.
-
(2014)
J. Med. Chem.
, vol.57
, pp. 921-936
-
-
Estrada, A.A.1
-
10
-
-
84862996255
-
Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations
-
Gilsbach B.K., et al. Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:10322-10327.
-
(2012)
Proc. Natl. Acad. Sci. U. S. A.
, vol.109
, pp. 10322-10327
-
-
Gilsbach, B.K.1
-
11
-
-
33746267531
-
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
-
Greggio E., et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 2006, 23:329-341.
-
(2006)
Neurobiol. Dis.
, vol.23
, pp. 329-341
-
-
Greggio, E.1
-
12
-
-
78651440972
-
Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?
-
Greggio E., et al. Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?. Mol. Neurodegener. 2011, 6:6.
-
(2011)
Mol. Neurodegener.
, vol.6
, pp. 6
-
-
Greggio, E.1
-
13
-
-
68649097307
-
The genetics of Parkinson's syndromes: a critical review
-
Hardy J., et al. The genetics of Parkinson's syndromes: a critical review. Curr. Opin. Genet. Dev. 2009, 19:254-265.
-
(2009)
Curr. Opin. Genet. Dev.
, vol.19
, pp. 254-265
-
-
Hardy, J.1
-
14
-
-
65449160605
-
The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel
-
Hassin-Baer S., et al. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. J. Neurol. 2009, 256:483-487.
-
(2009)
J. Neurol.
, vol.256
, pp. 483-487
-
-
Hassin-Baer, S.1
-
15
-
-
50049104725
-
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
-
Healy D.G., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008, 7:583-590.
-
(2008)
Lancet Neurol.
, vol.7
, pp. 583-590
-
-
Healy, D.G.1
-
16
-
-
84885452439
-
Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease
-
Hennis M.R., et al. Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease. Neurobiol. Dis. 2014, 62:113-123.
-
(2014)
Neurobiol. Dis.
, vol.62
, pp. 113-123
-
-
Hennis, M.R.1
-
17
-
-
80053968304
-
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice
-
Herzig M.C., et al. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum. Mol. Genet. 2011, 20:4209-4223.
-
(2011)
Hum. Mol. Genet.
, vol.20
, pp. 4209-4223
-
-
Herzig, M.C.1
-
18
-
-
84866145895
-
High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain
-
Herzig M.C., et al. High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS One 2012, 7:e36581.
-
(2012)
PLoS One
, vol.7
-
-
Herzig, M.C.1
-
19
-
-
33845796537
-
Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain
-
Higashi S., et al. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J. Neurochem. 2007, 100:368-381.
-
(2007)
J. Neurochem.
, vol.100
, pp. 368-381
-
-
Higashi, S.1
-
20
-
-
84861552733
-
LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors
-
Hinkle K.M., et al. LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol. Neurodegener. 2012, 7:25.
-
(2012)
Mol. Neurodegener.
, vol.7
, pp. 25
-
-
Hinkle, K.M.1
-
21
-
-
34447294546
-
Apoptotic mechanisms in mutant LRRK2-mediated cell death
-
Iaccarino C., et al. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum. Mol. Genet. 2007, 16:1319-1326.
-
(2007)
Hum. Mol. Genet.
, vol.16
, pp. 1319-1326
-
-
Iaccarino, C.1
-
22
-
-
34447118788
-
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity
-
Jaleel M., et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 2007, 405:307-317.
-
(2007)
Biochem. J.
, vol.405
, pp. 307-317
-
-
Jaleel, M.1
-
23
-
-
0032143368
-
Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat
-
Kirik D., et al. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 1998, 152:259-277.
-
(1998)
Exp. Neurol.
, vol.152
, pp. 259-277
-
-
Kirik, D.1
-
24
-
-
84879221281
-
Genome-wide association study signal at the 12q12 locus for Crohn's disease may represent associations with the MUC19 gene
-
Kumar V., et al. Genome-wide association study signal at the 12q12 locus for Crohn's disease may represent associations with the MUC19 gene. Inflamm. Bowel Dis. 2013, 19:1254-1259.
-
(2013)
Inflamm. Bowel Dis.
, vol.19
, pp. 1254-1259
-
-
Kumar, V.1
-
25
-
-
0015372223
-
Morphine catalepsy in the rat: relation to striatal dopamine metabolism
-
Kuschinsky K., Hornykiewicz O. Morphine catalepsy in the rat: relation to striatal dopamine metabolism. Eur. J. Pharmacol. 1972, 19:119-122.
-
(1972)
Eur. J. Pharmacol.
, vol.19
, pp. 119-122
-
-
Kuschinsky, K.1
Hornykiewicz, O.2
-
26
-
-
79955629341
-
Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human alpha-synuclein
-
Lam H.A., et al. Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human alpha-synuclein. J. Neurosci. Res. 2011, 89:1091-1102.
-
(2011)
J. Neurosci. Res.
, vol.89
, pp. 1091-1102
-
-
Lam, H.A.1
-
27
-
-
77956441086
-
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease
-
Lee B.D., et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat. Med. 2010, 16:998-1000.
-
(2010)
Nat. Med.
, vol.16
, pp. 998-1000
-
-
Lee, B.D.1
-
28
-
-
76149134717
-
Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S
-
Li X., et al. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci. 2010, 30:1788-1797.
-
(2010)
J. Neurosci.
, vol.30
, pp. 1788-1797
-
-
Li, X.1
-
29
-
-
79952302007
-
Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease
-
Li X., et al. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One 2011, 6:e17153.
-
(2011)
PLoS One
, vol.6
-
-
Li, X.1
-
30
-
-
72149087091
-
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein
-
Lin X., et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009, 64:807-827.
-
(2009)
Neuron
, vol.64
, pp. 807-827
-
-
Lin, X.1
-
31
-
-
80053152848
-
Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models
-
Liu Z., et al. Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum. Mol. Genet. 2011, 20:3933-3942.
-
(2011)
Hum. Mol. Genet.
, vol.20
, pp. 3933-3942
-
-
Liu, Z.1
-
32
-
-
33750931271
-
The Parkinson disease gene LRRK2: evolutionary and structural insights
-
Marin I. The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol. Biol. Evol. 2006, 23:2423-2433.
-
(2006)
Mol. Biol. Evol.
, vol.23
, pp. 2423-2433
-
-
Marin, I.1
-
33
-
-
3342929522
-
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior
-
Marti M., et al. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J. Neurosci. 2004, 24:6659-6666.
-
(2004)
J. Neurosci.
, vol.24
, pp. 6659-6666
-
-
Marti, M.1
-
34
-
-
27144554951
-
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease
-
Marti M., et al. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J. Neurosci. 2005, 25:9591-9601.
-
(2005)
J. Neurosci.
, vol.25
, pp. 9591-9601
-
-
Marti, M.1
-
35
-
-
33847003007
-
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway
-
Marti M., et al. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J. Neurosci. 2007, 27:1297-1307.
-
(2007)
J. Neurosci.
, vol.27
, pp. 1297-1307
-
-
Marti, M.1
-
36
-
-
33646151866
-
LRRK2 in Parkinson's disease: protein domains and functional insights
-
Mata I.F., et al. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 2006, 29:286-293.
-
(2006)
Trends Neurosci.
, vol.29
, pp. 286-293
-
-
Mata, I.F.1
-
37
-
-
84866510734
-
LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis
-
Matta S., et al. LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 2012, 75:1008-1021.
-
(2012)
Neuron
, vol.75
, pp. 1008-1021
-
-
Matta, S.1
-
38
-
-
34547107314
-
A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease
-
Melrose H.L., et al. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 2007, 147:1047-1058.
-
(2007)
Neuroscience
, vol.147
, pp. 1047-1058
-
-
Melrose, H.L.1
-
39
-
-
77957794336
-
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice
-
Melrose H.L., et al. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol. Dis. 2010, 40:503-517.
-
(2010)
Neurobiol. Dis.
, vol.40
, pp. 503-517
-
-
Melrose, H.L.1
-
40
-
-
84885989906
-
LRRK2 affects vesicle trafficking, neurotransmitter extracellular level and membrane receptor localization
-
Migheli R., et al. LRRK2 affects vesicle trafficking, neurotransmitter extracellular level and membrane receptor localization. PLoS One 2013, 8:e77198.
-
(2013)
PLoS One
, vol.8
-
-
Migheli, R.1
-
41
-
-
84891904255
-
Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3
-
Muda K., et al. Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E34-E43.
-
(2014)
Proc. Natl. Acad. Sci. U. S. A.
, vol.111
-
-
Muda, K.1
-
42
-
-
70350653779
-
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease
-
Nichols R.J., et al. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem. J. 2009, 424:47-60.
-
(2009)
Biochem. J.
, vol.424
, pp. 47-60
-
-
Nichols, R.J.1
-
43
-
-
8844266996
-
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease
-
Paisan-Ruiz C., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
-
(2004)
Neuron
, vol.44
, pp. 595-600
-
-
Paisan-Ruiz, C.1
-
44
-
-
84896736721
-
LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity
-
Parisiadou L., et al. LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. Nat. Neurosci. 2014, 17:367-376.
-
(2014)
Nat. Neurosci.
, vol.17
, pp. 367-376
-
-
Parisiadou, L.1
-
45
-
-
79951534656
-
LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool
-
Piccoli G., et al. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J. Neurosci. 2011, 31:2225-2237.
-
(2011)
J. Neurosci.
, vol.31
, pp. 2225-2237
-
-
Piccoli, G.1
-
46
-
-
79953758383
-
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2
-
Ramonet D., et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 2011, 6:e18568.
-
(2011)
PLoS One
, vol.6
-
-
Ramonet, D.1
-
47
-
-
43449090397
-
Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice
-
Rizzi A., et al. Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice. Br. J. Pharmacol. 2008, 154:471-479.
-
(2008)
Br. J. Pharmacol.
, vol.154
, pp. 471-479
-
-
Rizzi, A.1
-
48
-
-
0031402010
-
An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism
-
Rozas G., et al. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res. Brain Res. Protocol. 1997, 2:75-84.
-
(1997)
Brain Res. Brain Res. Protocol.
, vol.2
, pp. 75-84
-
-
Rozas, G.1
-
49
-
-
0023680943
-
The catalepsy test: its ups and downs
-
Sanberg P.R., et al. The catalepsy test: its ups and downs. Behav. Neurosci. 1988, 102:748-759.
-
(1988)
Behav. Neurosci.
, vol.102
, pp. 748-759
-
-
Sanberg, P.R.1
-
50
-
-
0035990918
-
The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway
-
Sasaki Y., et al. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol. Ther. 2002, 93:225-232.
-
(2002)
Pharmacol. Ther.
, vol.93
, pp. 225-232
-
-
Sasaki, Y.1
-
51
-
-
0018421663
-
Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism
-
Schallert T., et al. Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism. Exp. Neurol. 1979, 64:33-43.
-
(1979)
Exp. Neurol.
, vol.64
, pp. 33-43
-
-
Schallert, T.1
-
52
-
-
84874720265
-
Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations
-
164ra161
-
Sheng Z., et al. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci. Transl. Med. 2012, 4:164ra161.
-
(2012)
Sci. Transl. Med.
, vol.4
-
-
Sheng, Z.1
-
53
-
-
84891776413
-
Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies
-
Skibinski G., et al. Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J. Neurosci. 2014, 34:418-433.
-
(2014)
J. Neurosci.
, vol.34
, pp. 418-433
-
-
Skibinski, G.1
-
54
-
-
29444437871
-
Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration
-
Smith W.W., et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18676-18681.
-
(2005)
Proc. Natl. Acad. Sci. U. S. A.
, vol.102
, pp. 18676-18681
-
-
Smith, W.W.1
-
55
-
-
78650209340
-
Dopamine turnover increases in asymptomatic LRRK2 mutations carriers
-
Sossi V., et al. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov. Disord. 2010, 25:2717-2723.
-
(2010)
Mov. Disord.
, vol.25
, pp. 2717-2723
-
-
Sossi, V.1
-
56
-
-
29144527049
-
Development of specific Rho-kinase inhibitors and their clinical application
-
Tamura M., et al. Development of specific Rho-kinase inhibitors and their clinical application. Biochim. Biophys. Acta 2005, 1754:245-252.
-
(2005)
Biochim. Biophys. Acta
, vol.1754
, pp. 245-252
-
-
Tamura, M.1
-
57
-
-
77649105209
-
Mechanisms in dominant parkinsonism: the toxic triangle of LRRK2, alpha-synuclein, and tau
-
Taymans J.M., Cookson M.R. Mechanisms in dominant parkinsonism: the toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays 2010, 32:227-235.
-
(2010)
Bioessays
, vol.32
, pp. 227-235
-
-
Taymans, J.M.1
Cookson, M.R.2
-
58
-
-
70149124508
-
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice
-
Tong Y., et al. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14622-14627.
-
(2009)
Proc. Natl. Acad. Sci. U. S. A.
, vol.106
, pp. 14622-14627
-
-
Tong, Y.1
-
59
-
-
84879419522
-
Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2
-
Troxler T., et al. Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2. Bioorg. Med. Chem. Lett. 2013, 23:4085-4090.
-
(2013)
Bioorg. Med. Chem. Lett.
, vol.23
, pp. 4085-4090
-
-
Troxler, T.1
-
60
-
-
43649104203
-
Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism
-
Viaro R., et al. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiol. Dis. 2008, 30:430-438.
-
(2008)
Neurobiol. Dis.
, vol.30
, pp. 430-438
-
-
Viaro, R.1
-
61
-
-
28044460070
-
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
-
West A.B., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:16842-16847.
-
(2005)
Proc. Natl. Acad. Sci. U. S. A.
, vol.102
, pp. 16842-16847
-
-
West, A.B.1
-
62
-
-
84866657903
-
LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease
-
Xiong Y., et al. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease. Biochem. Soc. Trans. 2012, 40:1074-1079.
-
(2012)
Biochem. Soc. Trans.
, vol.40
, pp. 1074-1079
-
-
Xiong, Y.1
-
63
-
-
79960587095
-
Genetic LRRK2 models of Parkinson's disease: dissecting the pathogenic pathway and exploring clinical applications
-
Yue Z., Lachenmayer M.L. Genetic LRRK2 models of Parkinson's disease: dissecting the pathogenic pathway and exploring clinical applications. Mov. Disord. 2011, 26:1386-1397.
-
(2011)
Mov. Disord.
, vol.26
, pp. 1386-1397
-
-
Yue, Z.1
Lachenmayer, M.L.2
-
64
-
-
74049127960
-
Genomewide association study of leprosy
-
Zhang F.R., et al. Genomewide association study of leprosy. N. Engl. J. Med. 2009, 361:2609-2618.
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 2609-2618
-
-
Zhang, F.R.1
-
65
-
-
79960972765
-
Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake
-
Zhou H., et al. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int. J. Biol. Sci. 2011, 7:753-761.
-
(2011)
Int. J. Biol. Sci.
, vol.7
, pp. 753-761
-
-
Zhou, H.1
-
66
-
-
8844233579
-
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology
-
Zimprich A., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.
-
(2004)
Neuron
, vol.44
, pp. 601-607
-
-
Zimprich, A.1
|